Investors

ImmuCell Corporation (Nasdaq: ICCC) has developed the First Defense® product line to deliver Immediate Immunity™ against E. coli, coronavirus, and rotavirus infections, the primary pathogens that cause scours (uncontrolled diarrhea), which is the leading disease risk to newborn dairy and beef calves. The Company estimates the cost of scours in the US to be over $700 million per year. The use of First Defense® immediately after birth enables producers to realize the genetic potential of their newborn livestock assets.

The Company is also in the final stages of achieving FDA approval for Re-Tain™, a bacteriocin-based product to treat subclinical mastitis in lactating cows without the use of traditional human antibiotics. Mastitis infections result in approximately $2 BILLION in economic losses to the U.S. dairy industry annually. Reducing the use of antibiotics in the human food chain is a national imperative.

Annual Meeting of Stockholders

Wednesday, June 15, 2022 |  3:00PM ET

ImmuCell Announces Virtual-Only Annual Meeting of Stockholders

Annual Shareholder Meeting Webcast

Our Core Technology

CEO Michael Brigham discusses ImmuCell’s core technology with Dr. Joseph H. Crabb former Chief Scientific Officer and VP of Product Development for ImmuCell and the developer of First Defense.

Recent Events

ImmuCell at the Lytham Partners Summer 2022 Investor Conference
Tuesday, June 21, 2022
9:00AM ET

Conference Calls

ImmuCell First Quarter Fiscal Year 2022 Conference Call
Friday, May 13, 2022
9:00AM ET

02-23-21 – Fourth Quarter and Fiscal Year 2021 Conference Call

Webcast 

11-16-21 – Third Quarter Fiscal Year 2021 Conference Call

Webcast 

08-13-21 – Second Quarter Fiscal Year 2021 Conference Call

Webcast 

05-14-21 – First Quarter Fiscal Year 2021 Conference Call

Webcast